- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06664034
Intervening on Women's Health for Rural Young Cancer Survivors
August 26, 2026 updated by: Hui-Chun Irene Su, University of California, San Diego
The purpose of this pilot study is to evaluate the feasibility of a multi-component intervention to improve young female cancer survivors' engagement in goal-concordant reproductive health care.
The investigators hypothesize that implementation of the intervention will result in increased young cancer survivors' engagement in goal-concordant reproductive health care.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
42
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Brawley, California, United States, 92227
- San Diego State University - Imperial Valley/ School of Nursing
-
El Centro, California, United States, 92243
- El Centro Regional Medical Center
-
El Centro, California, United States, 92243
- Cancer Resource Center of the Desert
-
La Jolla, California, United States, 92093
- University of Califiornia San Diego
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Cancer (Stages 0-IV) diagnosis
- Primary language English or Spanish
- Receiving oncology care at rural oncology clinical participating site
- Living in Imperial County, California
Exclusion Criteria:
- Women who are pregnant at recruitment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Multi-component intervention
After the intervention implementation, all cancer patients presenting to oncology clinical visits that meet eligibility criteria will receive the multi-component intervention.
|
The multi-component reproductive health care intervention includes:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patient's engagement in goal-concordant reproductive health care
Time Frame: 12 weeks after oncology visit
|
Study staff will be trained to abstract the primary outcome from the patient's medical records using standardized case report forms.
Engagement in goal-concordant reproductive health care will be assigned to patients who undergo: 1) reproductive health needs screen and have no needs, OR 2) reproductive health needs screen, complete a navigation session and receive reproductive health counseling and management strategies, and have no further needs; OR 3) reproductive health needs screen, complete a navigation session and receive reproductive health counseling and management strategies, have a need, undergo a telehealth reproductive health consultation, and have no reproductive health service needs; OR 4) reproductive health needs screen, complete a navigation session and receive reproductive health counseling and management strategies, have a need, undergo a telehealth reproductive health consultation, have a reproductive health service needs, and uptake appropriate services.
|
12 weeks after oncology visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: H. Irene Su, MD, MSCE, University of California, San Diego
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2024
Primary Completion (Actual)
September 30, 2025
Study Completion (Actual)
May 31, 2026
Study Registration Dates
First Submitted
October 27, 2024
First Submitted That Met QC Criteria
October 27, 2024
First Posted (Actual)
October 29, 2024
Study Record Updates
Last Update Posted (Actual)
August 31, 2026
Last Update Submitted That Met QC Criteria
August 26, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- U54800646
- 5U54CA285115-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Deidentified individual participant data generated during the study will be available from the principal investigator (H.
Irene Su) upon reasonable request.
IPD Sharing Time Frame
Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.
IPD Sharing Access Criteria
Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.
Requests may be made to the principal investigator (H.
Irene Su).
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.